---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-059435"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:20:27.862666+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VYNE Q1 continuing ops loss $8.7M; divested MST franchise for $25M; positive FMX114 Phase 1b data

## Summary
- Q1 2022 GAAP loss from continuing ops $8.7M ($7.4M adjusted); net income $4.7M reflecting divestiture gain.
- Divested MST franchise (AMZEEQ, ZILXI) to Journey Medical for $25M upfront plus up to $450M milestones.
- FMX114 Phase 1b showed stat sig reduction in ADSI score vs vehicle; Phase 2a topline expected Q2 2022.
- VYN201 preclinical data demonstrated efficacy in rheumatoid arthritis and vitiligo models vs active controls.
- Entered $30M equity purchase agreement with Lincoln Park Capital over 36 months.

## SEC filing metadata
- accession: 0001104659-22-059435
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922059435/0001104659-22-059435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922059435/tm2215162d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-059435
- JSON: https://secwatch.observer/filing/0001104659-22-059435.json
- Plain text: https://secwatch.observer/filing/0001104659-22-059435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.